Two lawsuits filed by former top leaders alleged that LifeMD urged its clinicians to see more patients and mete out prescriptions more rapidly while providing little screening and follow-up.

LifeMD strenuously denies the allegations. The telehealth company faces these accusations as part of a broader industry landscape involving weight-loss medications.

Two former employees said providers at times were expected to review the cases of 25 people per hour based only on electronic forms the patients filled out. This volume of patient reviews relied exclusively on the data submitted through digital forms rather than direct clinical interaction.

Former employees said the company discouraged providers from asking what they felt were medically relevant questions to patients so that they do not "delay care." The internal guidance prioritized speed over additional inquiry during patient consultations.

LifeMD is a telehealth company. The organization operates within the digital health sector, connecting patients with medical providers through online platforms.

Novo Nordisk is the maker of Ozempic and Wegovy. These medications belong to the class of GLP-1 drugs used for weight management and diabetes treatment.

Nordisk lists LifeMD on its website as a provider that offers legitimate medicine sourcing and patient support for people seeking GLP-1 drugs. This listing identifies LifeMD as a resource for patients interested in these specific pharmaceutical treatments.

Experts say the industry of GLP-1 telehealth companies has been boosted by Nordisk and Eli Lilly. The growth of these telehealth services correlates with the market presence of major pharmaceutical manufacturers.

The allegations concern clinical practices within a telehealth model that has expanded alongside the demand for GLP-1 medications. Former employees and legal filings describe a system where high patient volume and rapid prescription cycles potentially reduced screening and follow-up care.

LifeMD denies these claims while maintaining a partnership status with Nordisk, which lists the company as a support provider for GLP-1 drugs. The industry context includes significant growth driven by major pharmaceutical companies, with LifeMD positioned as a key player in this expanding market.